FDA Inspection 1283250 — Saptalis Pharmaceuticals LLC
The FDA completed an inspection of Saptalis Pharmaceuticals LLC on September 9, 2025 in Hauppauge, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 9, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hauppauge, NY (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)